ArticleCell reports. Medicine2024
Hepatic glucose production rises with the histological severity of metabolic dysfunction-associated steatohepatitis.
Article in Cell reports. Medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Hepatic steatosis in humans is associated with preserved glucagon action on amino acid metabolism.The Journal of clinical investigation · 2026Trial
- Is MASLD an independent risk factor for micro- and macrovascular complications of diabetes? A critical reappraisal and future directions.Diabetologia · 2026Review
- Article
- Oral glucose absorption is enhanced in early metabolic dysfunction-associated steatotic liver disease.Diabetologia · 2026Article
- Metabolic drivers of MASLD and MASH: from hormonal imbalance to fibrosis.Diabetologia · 2026Review
- Neuromodulation using Bioelectronics-enabled therapies to combat insulin resistance and its comorbidities.Journal of diabetes and metabolic disorders · 2026Review
- Integrated transcriptomic analysis identifies liver aging-driven fibrosis signatures and reveals therapeutic strategies based on medicine-food homology.NPJ science of food · 2026Article
- Article
- Incretin and Glucagon Signalling in MASLD and MASH: Integrating Metabolic Pathways With Disease Progression.Diabetes, obesity & metabolism · 2026Review
- Human MASLD is a diurnal disease driven by multisystem insulin resistance and reduced insulin availability at night.Cell metabolism · 2026Observational
- Sex-specific aspects in the development of tissue metabolic damage in a non-obese prediabetic model.Frontiers in endocrinology · 2026Article
- Beyond glucose: wearable and implantable biosensors for continuous monitoring of metabolic, hormonal, and inflammatory biomarkers in personalized cardiometabolic care.Frontiers in bioengineering and biotechnology · 2026Review
- Association between metabolic dysfunction-associated steatotic liver disease and kidney stone risk in individuals with metabolic dysfunction: evidence from cross-sectional and cohort analyses.Frontiers in endocrinology · 2026Article
- First-trimester fatty liver index and hepatic steatosis index independently predict gestational diabetes risk: a prospective cohort study.Frontiers in nutrition · 2026Article
- Metabolic characteristics and factors associated with prediabetes in Chinese adults based on real-world health examination data: a cross-sectional study.Frontiers in nutrition · 2026Article
- Close multilevel links between metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus.Metabolism open · 2025Review
- The beneficial effect of hepatic ER stress-associated protein PDI on obesity-associated glucose dysregulation.Nutrition & metabolism · 2025Article
- Roles of short-chain fatty acids in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis.World journal of hepatology · 2025Review
- Review
- Microdroplet Mass Spectrometry Enables Rapid and Sensitive Measurement of Glucose Homeostasis for Elucidating Mechanism of Drug Action.Analytical chemistry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis (MASH) are associated with a high prevalence of type 2 diabetes (T2D). Individuals with MASLD exhibit insulin resistance (IR) and hyperglycemia, but it is unclear whether hepatic glucose production (HGP) is increased with MASLD severity. We evaluated HGP in a cohort of histologically characterized individuals with MASL/MASH using stable isotope infusion (6,6-
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.